Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

21. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144854 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1785-6. doi: 10.1056/NEJMc1602338. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27144854 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments

NEJM2016

22. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144855 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1785. doi: 10.1056/NEJMc1602338#SA1. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 1 , 1 , 1 . 1 University Hospital of Bern, Bern, Switzerland daniele.bolla@insel.ch. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27144855 DOI: [Indexed for MEDLINE] Publication

NEJM2016 Full Text: Link to full Text with Trip Pro

23. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. BACKGROUND: The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in women with suspected preeclampsia is unclear. METHODS: We performed a prospective, multicenter, observational study to derive and validate a ratio of serum sFlt-1 to PlGF that would be predictive of the absence (...) or presence of preeclampsia in the short term in women with singleton pregnancies in whom preeclampsia was suspected (24 weeks 0 days to 36 weeks 6 days of gestation). Primary objectives were to assess whether low sFlt-1:PlGF ratios (at or below a derived cutoff) predict the absence of preeclampsia within 1 week after the first visit and whether high ratios (above the cutoff) predict the presence of preeclampsia within 4 weeks. RESULTS: In the development cohort (500 women), we identified an sFlt-1:PlGF

NEJM2016

24. Improving the Prediction of Preeclampsia.

Improving the Prediction of Preeclampsia. Improving the Prediction of Preeclampsia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26735997 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jan 7;374(1):83-4. doi: 10.1056/NEJMe1515223. Improving the Prediction of Preeclampsia. 1 , . 1 From the Endocrinology, Diabetes, and Hypertension Division, Brigham and Women's Hospital, Boston (E.W.S.). Comment on [N Engl J Med. 2016] PMID: 26735997 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed

NEJM2016

25. Association Between Preeclampsia and Congenital Heart Defects.

Association Between Preeclampsia and Congenital Heart Defects. IMPORTANCE: The risk of congenital heart defects in infants of women who had preeclampsia during pregnancy is poorly understood, despite shared angiogenic pathways in both conditions. OBJECTIVE: To determine the prevalence of congenital heart defects in offspring of women with preeclampsia. DESIGN, SETTING, AND PARTICIPANTS: Population-level analysis of live births before discharge, 1989-2012, was conducted for the entire province (...) of Quebec, comprising a quarter of Canada's population. All women who delivered an infant with or without heart defects in any Quebec hospital were included (N = 1,942,072 neonates). EXPOSURES: Preeclampsia or eclampsia with onset before or after 34 weeks of gestation. MAIN OUTCOMES AND MEASURES: Presence of any critical or noncritical congenital heart defect detected in infants at birth, comparing prevalence in those exposed and not exposed to preeclampsia. RESULTS: The absolute prevalence

JAMA2015

26. Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Article Text Midwifery Systematic review with meta-analysis Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Emmanuel Bujold

Evidence-Based Nursing (Requires free registration)2015

27. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review

Evidence-Based Medicine (Requires free registration)2015

28. First-Trimester Risk Assessment for Early-Onset Preeclampsia

First-Trimester Risk Assessment for Early-Onset Preeclampsia First-Trimester Risk Assessment for Early-Onset Preeclampsia - ACOG Menu ▼ First-Trimester Risk Assessment for Early-Onset Preeclampsia Page Navigation ▼ Number 638, September 2015 (Reaffirmed 2017) Committee on Obstetric Practice This document has been endorsed by the Society for Maternal–Fetal Medicine. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information (...) should not be construed as dictating an exclusive course of treatment or procedure to be followed. First-Trimester Risk Assessment for Early-Onset Preeclampsia ABSTRACT: Hypertensive disorders with adverse sequelae (including preterm birth, maternal morbidity and mortality, and long-term risk of maternal cardiovascular disease) complicate 5–10% of pregnancies. Early identification of pregnant women at risk of developing early-onset preeclampsia would theoretically allow referral for more intensive

American College of Obstetricians and Gynecologists2015

29. Gestational Hypertension and Preeclampsia in Living Kidney Donors.

Gestational Hypertension and Preeclampsia in Living Kidney Donors. BACKGROUND: Young women wishing to become living kidney donors frequently ask whether nephrectomy will affect their future pregnancies. METHODS: We conducted a retrospective cohort study of living kidney donors involving 85 women (131 pregnancies after cohort entry) who were matched in a 1:6 ratio with 510 healthy nondonors from the general population (788 pregnancies after cohort entry). Kidney donations occurred between 1992 (...) and 2009 in Ontario, Canada, with follow-up through linked health care databases until March 2013. Donors and nondonors were matched with respect to age, year of cohort entry, residency (urban or rural), income, number of pregnancies before cohort entry, and the time to the first pregnancy after cohort entry. The primary outcome was a hospital diagnosis of gestational hypertension or preeclampsia. Secondary outcomes were each component of the primary outcome examined separately and other maternal

NEJM2014 Full Text: Link to full Text with Trip Pro

30. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement.

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. DESCRIPTION: Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy. METHODS: The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed (...) the maternal and fetal harms of low-dose aspirin during pregnancy. POPULATION: This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin. RECOMMENDATION: The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

Annals of Internal Medicine2014

31. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.

Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. BACKGROUND: Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. PURPOSE: To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia. DATA SOURCES: MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled (...) Trials (January 2006 to June 2013); previous systematic reviews, clinical trial registries, and surveillance searches for large studies (June 2013 to February 2014). STUDY SELECTION: Randomized, controlled trials (RCTs) to assess benefits among women at high preeclampsia risk and RCTs or large cohort studies of harms among women at any risk level. English-language studies of fair or good quality were included. DATA EXTRACTION: Dual quality assessment and abstraction of studies. DATA SYNTHESIS: Two

Annals of Internal Medicine2014

32. Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia

Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia UTCAT2704, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia Clinical Question Is periodontitis a risk factor for development of preeclampsia during pregnancy? Clinical Bottom Line Research has shown that periodontal disease (...) contributes to the development of preeclampsia during pregnancy. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Sgolastra/2013 384 studies Meta-Analysis Key results This meta-analysis concluded that a relationship between pregnant women with periodontal disease (PD) and development of preeclampsia (PE) does indeed exist. Originally, 384 studies were reviewed; however, only 15 studies qualified for inclusion

UTHSCSA Dental School CAT Library2014

33. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms

Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms 25471057 2015 11 21 2016 03 07 2016 11 26 1471-0528 122 13 2015 Dec BJOG : an international journal of obstetrics and gynaecology BJOG Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. 1781-8 10.1111/1471-0528.13194 To evaluate two algorithms for prediction of preeclampsia in a population (...) with the Preeclampsia Predictor TM version 1 revision 2 by Perkin Elmer (PREDICTOR). Prediction of preeclampsia requiring delivery before 37 weeks, before 42 weeks and late preeclampsia (delivery after 34 weeks). The performance of the two algorithms was similar, but quite poor, for prediction of preeclampsia requiring delivery before 42 weeks with an area under the curve of 0.77 (0.67-0.87) and sensitivity 40% (95% CI 19.1-63.9) at a fixed 10% false positive rate for FMF and 0.74 (0.63-0.84) and sensitivity 30

EvidenceUpdates2014

34. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial

Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial 23954534 2013 11 11 2014 01 06 2014 09 11 1097-6868 209 5 2013 Nov American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial. 425.e1-8 10.1016/j.ajog.2013.08.016 S0002-9378(13)00842-9 The objective of the study was to determine (...) whether expectant management of severe preeclampsia prior to 34 weeks of gestation results in improved neonatal outcome in countries with limited resources. This was a randomized clinical trial performed in 8 tertiary hospitals in Latin America. Criteria of randomization included gestational age between 28 and 33 weeks' gestation and the presence of severe hypertensive disorders. Patients were randomized to steroids with prompt delivery (PD group) after 48 hours vs steroids and expectant management

EvidenceUpdates2014

35. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication Final Update Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive (...) Medication Release Date: September 2014 Recommendation Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia Population Recommendation Grade Pregnant Women Who Are At High Risk for Preeclampsia The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information

U.S. Preventive Services Task Force2014

36. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study

Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study 24190934 2013 11 05 2014 01 28 2016 11 25 1524-4539 128 19 2013 Nov 05 Circulation Circulation Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. 2121-31 10.1161/CIRCULATIONAHA.113.003215 Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants (...) . The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental dysfunction in preeclampsia, with known low plasma concentrations in the disease. In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting

EvidenceUpdates2013

37. Antioxidants for preventing preeclampsia: a systematic review

Antioxidants for preventing preeclampsia: a systematic review Antioxidants for preventing preeclampsia: a systematic review Antioxidants for preventing preeclampsia: a systematic review Salles AM, Galvao TF, Silva MT, Motta LC, Pereira MG CRD summary This review found there were no significant differences in the incidence of pre-eclampsia in pregnant women after treatment with antioxidants. The risk of publication bias and variation in patients and treatments across the trials mean (...) that the authors' conclusions should be interpreted with caution and their reliability is uncertain. Authors' objectives To assess the efficacy of antioxidants, in preventing pre-eclampsia and other maternal and foetal complications, for pregnant women at low, moderate, or high risk of pre-eclampsia. Searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), metaRegister of Controlled Trials, CRD databases, Web of Science, Scopus, LILACS, and SciELO were searched to October 2011

DARE.2012

38. Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia

Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia 22939731 2012 09 03 2012 11 13 2013 11 21 1097-6868 207 3 2012 Sep American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia. 233.e1-8 10.1016/j.ajog.2012.06.010 The purpose of this study was to evaluate the performance of the 12-hour (...) urine protein >165 mg and protein:creatinine ratio >0.15 for the prediction of 24-hour urine protein of ≥300 mg in patients with suspected preeclampsia. We performed a prospective observational study of 90 women who had been admitted with suspected preeclampsia. Protein:creatinine ratio and 12- and 24-hour urine specimens were collected for each patient. Test characteristics for the identification of 24-hour urine protein ≥300 mg were calculated. A 12-hour urine protein >165 mg

EvidenceUpdates2012

39. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays

Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays 21903191 2011 10 31 2012 01 17 2016 11 25 1097-6868 205 5 2011 Nov American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. 469.e1-8 10.1016/j.ajog.2011.06.058 Placental growth factor and soluble Fms-like tyrosine kinase-1 may be potential (...) diagnostic markers of preeclampsia. We compared performances of 2 immunoassays, the Triage placental growth factor assay and the Elecsys soluble Fms-like tyrosine kinase-1/placental growth factor ratio in diagnosing preeclampsia. A single site, case-control study of 44 patients with preeclampsia and 84 matched normal pregnant controls. Samples were collected at the time of diagnosis. Assays were performed according to product inserts. Both assays had optimal performance in diagnosing early-onset

EvidenceUpdates2012

40. Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths

Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths Jabeen M, Yakoob MY, Imdad A, Bhutta ZA CRD summary This review concluded that despite promising benefits of calcium supplementation and aspirin use on maternal morbidity and eclampsia in high-risk cases, further work was needed (...) on stillbirths (RR 0.81, 95% CI 0.63 to 1.03; three RCTs) or perinatal mortality (RR 0.86, 95% CI 0.70 to 1.07; four RCTs). For antihypertensive agents in pregnancy with mild to moderate hypertension, studies did not show a statistically significant effect of antihypertensives on stillbirths (18 RCTs) or perinatal mortality (20 RCTs). For magnesium sulphate in pregnancy with pre-eclampsia, studies did not show a statistically significant effect of magnesium sulphate on stillbirths (three RCTs) or perinatal

DARE.2011